ARK2N

Summary

ARK2N (arkadia (RNF111) N-terminal like PKA signaling regulator 2N, HGNC:28172) is a protein-coding gene on chromosome 18q21.1, encoding Protein ARK2N (Q96B23). AMPK substrate important for exercise capacity and skeletal muscle function.

Enables transcription corepressor activity. Involved in negative regulation of viral life cycle. Is active in chromatin.

Source: NCBI Gene 147339 — RefSeq curated summary.

At a glance

• GWAS associations: 46
• Clinical variants (ClinVar): 12 total — 1 pathogenic
• MANE Select transcript: NM_145055

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:28172
Approved symbol	ARK2N
Name	arkadia (RNF111) N-terminal like PKA signaling regulator 2N
Location	18q21.1
Locus type	gene with protein product
Status	Approved
Aliases	MGC12909, ARKL1, RNF111L1, Ark2N
Ensembl gene	ENSG00000152242
Ensembl biotype	protein_coding
OMIM	621303
Entrez	147339

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 10 protein_coding, 1 retained_intron

ENST00000587591, ENST00000588730, ENST00000615052, ENST00000615553, ENST00000619230, ENST00000619301, ENST00000905557, ENST00000905558, ENST00000915807, ENST00000915808, ENST00000951697

RefSeq mRNA: 2 — MANE Select: NM_145055 NM_001008239, NM_145055

CCDS: CCDS42430, CCDS42431

Canonical transcript exons

ENST00000615052 — 5 exons

Exon	Start	End
ENSE00003717731	46253697	46253823
ENSE00003718340	46215811	46216595
ENSE00003734719	46240005	46240187
ENSE00003736085	46174034	46174330
ENSE00003747474	46262929	46266992

Expression profiles

Bgee: expression breadth ubiquitous, 268 present calls, max score 97.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.6692 / max 684.2413, expressed in 1799 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
170152	7.7287	1724
170151	4.7072	1643
170149	1.8747	807
170153	1.4916	467
170148	0.8671	480

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	97.48	gold quality
lower esophagus mucosa	UBERON:0035834	96.04	gold quality
esophagus squamous epithelium	UBERON:0006920	94.77	gold quality
biceps brachii	UBERON:0001507	93.33	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	92.80	gold quality
epithelium of esophagus	UBERON:0001976	92.64	gold quality
heart right ventricle	UBERON:0002080	91.94	gold quality
caput epididymis	UBERON:0004358	91.52	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	91.23	gold quality
palpebral conjunctiva	UBERON:0001812	91.08	gold quality
oral cavity	UBERON:0000167	90.68	gold quality
esophagus mucosa	UBERON:0002469	90.34	gold quality
cauda epididymis	UBERON:0004360	90.19	gold quality
pharyngeal mucosa	UBERON:0000355	90.18	gold quality
Brodmann (1909) area 23	UBERON:0013554	89.86	gold quality
corpus epididymis	UBERON:0004359	89.35	gold quality
amniotic fluid	UBERON:0000173	89.32	gold quality
body of tongue	UBERON:0011876	88.73	gold quality
squamous epithelium	UBERON:0006914	88.43	gold quality
upper leg skin	UBERON:0004262	88.34	gold quality
superior surface of tongue	UBERON:0007371	88.06	gold quality
pigmented layer of retina	UBERON:0001782	87.97	gold quality
tongue	UBERON:0001723	87.52	gold quality
skin of hip	UBERON:0001554	87.26	gold quality
tonsil	UBERON:0002372	87.22	gold quality
gastrocnemius	UBERON:0001388	87.06	gold quality
muscle of leg	UBERON:0001383	86.82	gold quality
trabecular bone tissue	UBERON:0002483	86.68	gold quality
colonic epithelium	UBERON:0000397	86.41	gold quality
epithelium of nasopharynx	UBERON:0001951	86.28	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-MTAB-6386	no	671.93
E-ANND-3	no	4.36

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

256 targeting ARK2N, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-656-3P	100.00	72.15	2788
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-3662	99.99	73.82	5684

Literature-anchored findings (GeneRIF, showing 2)

• ARKL1 binds CK2beta through the KSSR motif and this involves a polyserine sequence resembling the CK2beta binding sequence in EBNA1. (PMID:24216761)
• Phosphoproteomics of three exercise modalities identifies canonical signaling and C18ORF25 as an AMPK substrate regulating skeletal muscle function. (PMID:35882232)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ark2n	ENSDARG00000046071
mus_musculus	Ark2n	ENSMUSG00000047466
rattus_norvegicus	Ark2n	ENSRNOG00000017215
drosophila_melanogaster	CG6923	FBGN0037944
caenorhabditis_elegans	toe-4	WBGENE00012194

Paralogs (2): ARK2C (ENSG00000141622), RNF111 (ENSG00000157450)

Protein

Protein identifiers

Protein ARK2N — Q96B23 (reviewed: Q96B23)

Alternative names: ARKadia-like protein 1, Arkadia (RNF111) N-terminal like PKA signaling regulator protein 2N

All UniProt accessions (4): Q96B23, A0A087WVF1, K7EQH1, K7ER64

UniProt curated annotations — full annotation on UniProt →

Function. AMPK substrate important for exercise capacity and skeletal muscle function. Required for normal contraction-induced signaling. (Microbial infection) Upon Epstein-Barr virus (EBV) infection, suppresses viral BZLF1 expression and subsequent EBV reactivation by interacting with JUN and inhibiting its transcriptional activator activity on BZLF1 Z promoter.

Subunit / interactions. Interacts with CSNK2B (via KSSR). Interacts with JUN; the interaction is mediated by CSNK2B.

Subcellular location. Nucleus.

Tissue specificity. Expressed in skeletal muscle.

Post-translational modifications. Phosphorylated at Ser-67 by AMPK. In skeletal muscle, phosphorylation is induced by exercise and seems to increase muscle contractile function.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96B23-1	1	yes
Q96B23-2	2

RefSeq proteins (2): NP_001008240, NP_659492* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029306	RNF111_N	Domain
IPR051073	ZNRF3_Arkadia_E3_ligases	Family

Pfam: PF15303

UniProt features (26 total): modified residue 9, compositionally biased region 5, region of interest 3, mutagenesis site 2, sequence conflict 2, chain 1, cross-link 1, splice variant 1, sequence variant 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96B23-F1	54.67	0.04

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (10): 66, 67, 143, 145, 147, 327, 328, 330, 347, 358

Mutagenesis-validated functional residues (2):

Position	Phenotype
66–67	loss of phosphorylation by ampk. decreases muscle specific force.
66–67	increased phosphorylation. increases muscle specific force.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 201 (showing top): AAGCAAT_MIR137, TGCACTT_MIR519C_MIR519B_MIR519A, GOBP_NEGATIVE_REGULATION_OF_VIRAL_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, BROWNE_HCMV_INFECTION_16HR_UP, ATGCAGT_MIR217, FOXO1_01, BROWNE_HCMV_INFECTION_12HR_UP, ATGTTAA_MIR302C, TCF4_Q5, GGGCATT_MIR365, WTGAAAT_UNKNOWN, GOBP_VIRAL_LIFE_CYCLE, MORF_EPHA7, TTGGAGA_MIR5155P_MIR519E

GO Biological Process (4): ubiquitin-dependent protein catabolic process (GO:0006511), negative regulation of viral life cycle (GO:1903901), release from viral latency (GO:0019046), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (3): transcription corepressor activity (GO:0003714), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515)

GO Cellular Component (2): chromatin (GO:0000785), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein ubiquitination	1
modification-dependent protein catabolic process	1
viral life cycle	1
negative regulation of viral process	1
regulation of viral life cycle	1
viral process	1
latent virus replication	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
transcription coregulator activity	1
negative regulation of DNA-templated transcription	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
binding	1
chromosome	1
cellular anatomical structure	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

706 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARK2N	ARK2C	Q6ZSG1	645
ARK2N	FAM240B	A0A1B0GVZ2	507
ARK2N	TMEM200C	A6NKL6	479
ARK2N	A6NLF2	A6NLF2	448
ARK2N	Q3MI93	Q3MI93	417
ARK2N	TMEM200A	Q86VY9	391
ARK2N	RHNO1	Q9BSD3	368
ARK2N	FUNDC2	Q9BWH2	361
ARK2N	LOXHD1	Q8IVV2	341
ARK2N	IER3IP1	Q9Y5U9	324
ARK2N	ZNF764	Q96H86	323
ARK2N	FRG2C	A6NGY1	322
ARK2N	HOATZ	Q6PI97	310
ARK2N	HDHD2	Q9H0R4	305
ARK2N	Q8NG57	Q8NG57	300

IntAct

131 interactions, top by confidence:

A	B	Type	Score
ATF2	JUN	psi-mi:“MI:0914”(association)	0.950
MED17	MED19	psi-mi:“MI:0914”(association)	0.840
CSNK2A1	EIF3J	psi-mi:“MI:0914”(association)	0.810
SUMO1	ARK2N	psi-mi:“MI:0915”(physical association)	0.790
ARK2N	SUMO1	psi-mi:“MI:0915”(physical association)	0.790
SUMO1	ARK2N	psi-mi:“MI:0407”(direct interaction)	0.790
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
INO80E	TFPT	psi-mi:“MI:0914”(association)	0.790
NRP1	CSNK2A2	psi-mi:“MI:0914”(association)	0.790
CSNK2B	RPS6KA5	psi-mi:“MI:0914”(association)	0.660
CSNK2B	NMT2	psi-mi:“MI:0914”(association)	0.660
RPS6KA3	ROCK2	psi-mi:“MI:0914”(association)	0.640
CSNK2B	RPS6KA4	psi-mi:“MI:0914”(association)	0.640
CAMKV	AP3B1	psi-mi:“MI:0914”(association)	0.640
CSNK2A2	PES1	psi-mi:“MI:0914”(association)	0.640
HOXC9	AHCYL1	psi-mi:“MI:0914”(association)	0.640
TULP3	GGPS1	psi-mi:“MI:0914”(association)	0.640
ARK2N	SUMO1P1	psi-mi:“MI:0915”(physical association)	0.560
TAX1BP1	ARK2N	psi-mi:“MI:0915”(physical association)	0.560
ARK2N	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
ARK2N	MCRS1	psi-mi:“MI:0915”(physical association)	0.560
ARK2N	JAKMIP1	psi-mi:“MI:0915”(physical association)	0.560
RNF4	ARK2N	psi-mi:“MI:0915”(physical association)	0.560
UBE2I	ARK2N	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (173): C18orf25 (Two-hybrid), SUMO1P1 (Two-hybrid), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Two-hybrid), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS), C18orf25 (Affinity Capture-MS)

ESM2 similar proteins: A2VE56, A6QPH9, I3LHS8, O08781, O14545, O54836, P0C6S7, Q14CM0, Q3SZY7, Q3U2E2, Q497H0, Q4R3D6, Q4R970, Q58D05, Q5F3F2, Q5FWF5, Q5R7S6, Q5RDJ2, Q5U2M7, Q5VT97, Q66J85, Q68FE8, Q69Z69, Q6DGF4, Q6FIF0, Q6N043, Q6P2K3, Q70EL2, Q7Z6G8, Q8BIZ1, Q8IWR0, Q8K214, Q8K387, Q8N7W2, Q8N9Z9, Q8NA31, Q8ND82, Q8QFX1, Q91YD3, Q96B23

Diamond homologs: Q5R4B7, Q8BH50, Q96B23, Q5R476, Q66J97, Q6NRV8, Q6ZNA4, Q90ZT7, Q99ML9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 149 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SPOP-mediated proteasomal degradation of PD-L1(CD274)	5	11.3×	6e-03
Regulation of PTEN stability and activity	5	9.1×	9e-03
Toll-like Receptor Cascades	7	8.6×	4e-03
UCH proteinases	6	7.4×	9e-03
Regulation of TP53 Activity through Phosphorylation	6	7.0×	9e-03
Viral Infection Pathways	13	4.0×	4e-03
Infectious disease	16	3.9×	2e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of cell cycle	11	6.0×	1e-03
protein phosphorylation	10	5.0×	8e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

12 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	2
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1180529	GRCh37/hg19 18q11.2-23(chr18:23626739-78014976)x3	Pathogenic

SpliceAI

1869 predictions. Top by Δscore:

Variant	Effect	Δscore
18:46174331:GTGAG:G	donor_loss	1.0000
18:46216602:G:GT	donor_gain	1.0000
18:46224233:T:TA	donor_gain	1.0000
18:46224234:A:AA	donor_gain	1.0000
18:46253692:CTCA:C	acceptor_loss	1.0000
18:46253694:CAG:C	acceptor_loss	1.0000
18:46253695:A:AG	acceptor_gain	1.0000
18:46253695:AGGT:A	acceptor_loss	1.0000
18:46253696:G:GG	acceptor_gain	1.0000
18:46253696:GGT:G	acceptor_gain	1.0000
18:46253696:GGTC:G	acceptor_gain	1.0000
18:46253789:G:GT	donor_gain	1.0000
18:46253820:CAAGG:C	donor_loss	1.0000
18:46253821:AAG:A	donor_loss	1.0000
18:46253822:AGGT:A	donor_loss	1.0000
18:46253824:G:GA	donor_loss	1.0000
18:46253825:T:A	donor_loss	1.0000
18:46254659:T:G	acceptor_gain	1.0000
18:46254661:T:G	acceptor_gain	1.0000
18:46254662:A:AG	acceptor_gain	1.0000
18:46263099:GGC:G	donor_gain	1.0000
18:46263100:GCG:G	donor_gain	1.0000
18:46174332:T:A	donor_loss	0.9900
18:46212817:GCGTT:G	donor_gain	0.9900
18:46215806:TACA:T	acceptor_loss	0.9900
18:46215809:AGGT:A	acceptor_loss	0.9900
18:46216591:ACCAG:A	donor_loss	0.9900
18:46216592:CCAG:C	donor_loss	0.9900
18:46216593:CAG:C	donor_loss	0.9900
18:46216594:AGGT:A	donor_loss	0.9900

AlphaMissense

2633 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:46216441:G:C	R187S	1.000
18:46216441:G:T	R187S	1.000
18:46216420:G:C	K180N	0.999
18:46216420:G:T	K180N	0.999
18:46216426:G:C	R182S	0.999
18:46216426:G:T	R182S	0.999
18:46216440:G:C	R187T	0.999
18:46216440:G:T	R187M	0.999
18:46216449:G:C	R190P	0.999
18:46216490:A:C	S204R	0.999
18:46216492:T:A	S204R	0.999
18:46216492:T:G	S204R	0.999
18:46216493:A:C	S205R	0.999
18:46216495:T:A	S205R	0.999
18:46216495:T:G	S205R	0.999
18:46216499:A:C	S207R	0.999
18:46216501:T:A	S207R	0.999
18:46216501:T:G	S207R	0.999
18:46263078:T:C	L392P	0.999
18:46216178:A:C	S100R	0.998
18:46216180:T:A	S100R	0.998
18:46216180:T:G	S100R	0.998
18:46216425:G:C	R182T	0.998
18:46216434:T:C	L185P	0.998
18:46216437:T:C	L186P	0.998
18:46216193:G:C	D105H	0.997
18:46216345:G:C	K155N	0.997
18:46216345:G:T	K155N	0.997
18:46216425:G:T	R182M	0.997
18:46216447:A:C	K189N	0.997

dbSNP variants (sampled 300 via entrez): RS1000039705 (18:46172436 G>A), RS1000088452 (18:46249990 C>G,T), RS1000095526 (18:46258083 T>C), RS1000113210 (18:46200688 T>C), RS1000130261 (18:46207056 A>G), RS1000186152 (18:46234801 A>G), RS1000186901 (18:46194542 G>A,T), RS1000244482 (18:46244697 G>A), RS1000346177 (18:46200559 GC>G), RS1000373965 (18:46195186 A>C,G), RS1000420777 (18:46245025 G>A), RS1000451243 (18:46264582 A>G), RS1000466994 (18:46189288 C>T), RS1000514444 (18:46183183 G>A), RS1000535341 (18:46230738 C>T)

Disease associations

OMIM: gene MIM:621303 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

46 associations (top):

Study	Trait	p-value
GCST003540_7	Clinical laboratory measurements	2.000000e-10
GCST003540_8	Clinical laboratory measurements	2.000000e-13
GCST004599_132	Mean platelet volume	2.000000e-13
GCST004601_179	Red blood cell count	5.000000e-25
GCST004602_253	Mean corpuscular volume	5.000000e-74
GCST004610_86	White blood cell count	5.000000e-10
GCST004611_139	High light scatter reticulocyte count	7.000000e-10
GCST004613_69	Sum neutrophil eosinophil counts	8.000000e-10
GCST004614_69	Granulocyte count	2.000000e-09
GCST004620_33	Sum basophil neutrophil counts	3.000000e-09
GCST004621_201	Red cell distribution width	1.000000e-109
GCST004621_202	Red cell distribution width	9.000000e-121
GCST004622_65	Reticulocyte count	3.000000e-13
GCST004626_152	Myeloid white cell count	1.000000e-10
GCST004629_38	Neutrophil count	2.000000e-09
GCST004630_224	Mean corpuscular hemoglobin	3.000000e-79
GCST005993_18	Mean corpuscular hemoglobin	7.000000e-22
GCST006011_56	Mean corpuscular volume	3.000000e-22
GCST006804_16	Red cell distribution width	5.000000e-85
GCST006996_3	Cerebrospinal AB1-42 levels in mild cognitive impairment	3.000000e-06
GCST007012_5	Cerebrospinal fluid AB1-42 levels	1.000000e-07
GCST90002381_549	Eosinophil count	3.000000e-09
GCST90002384_434	Hemoglobin	2.000000e-12
GCST90002385_337	High light scatter reticulocyte count	6.000000e-10
GCST90002386_86	High light scatter reticulocyte percentage of red cells	3.000000e-28
GCST90002387_212	Immature fraction of reticulocytes	4.000000e-13
GCST90002389_248	Lymphocyte percentage of white cells	6.000000e-09
GCST90002390_552	Mean corpuscular hemoglobin	9.000000e-46
GCST90002390_553	Mean corpuscular hemoglobin	7.000000e-40
GCST90002391_100	Mean corpuscular hemoglobin concentration	5.000000e-20

EFO canonical traits (15, from GWAS)

EFO ID	Trait name
EFO:0004297	clinical laboratory measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0004305	erythrocyte count
EFO:0007986	reticulocyte count
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0005090	basophil count
EFO:0009188	Red cell distribution width
EFO:0004670	beta-amyloid 1-42 measurement
EFO:0004509	hemoglobin measurement
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0005091	monocyte count
EFO:0010701	mean reticulocyte volume

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
GSK-J4	increases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
methylmercuric chloride	increases expression	1
deoxynivalenol	increases expression	1
arsenite	decreases methylation	1
sodium arsenite	increases abundance, increases expression	1
coumarin	decreases phosphorylation	1
pentabromodiphenyl ether	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Acetaminophen	increases expression	1
Arsenic	increases abundance, increases expression	1
Benzo(a)pyrene	increases expression	1
Caffeine	affects phosphorylation	1
Demecolcine	increases expression	1
Doxorubicin	decreases expression	1
Drugs, Chinese Herbal	increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1
Ivermectin	decreases expression	1
Lead	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Naphthoquinones	increases expression	1
Thiram	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.